Oral small molecule GLP-1 receptor agonist
Orforglipron maximum tolerated dose tablet once daily
ORFO_PO_MTD_24-36_QD
Related
- All doses pooled: Orforglipron tablet
- Orforglipron 12 mg oral once daily
- Orforglipron 36 mg oral once daily
- Orforglipron 6 mg oral once daily
- Orforglipron 3 mg oral once daily
- Orforglipron 1 mg tablet once daily
- Orforglipron 14.5 mg tablet once daily
- Orforglipron 17.2 mg tablet once daily
- Orforglipron 0.8 mg tablet once daily
- Orforglipron 2.5 mg tablet once daily
- Orforglipron 5.5 mg tablet once daily
- Orforglipron 9 mg tablet once daily
- Orforglipron 24 mg oral once daily
- Orforglipron 45 mg oral once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Weight maintenance after a GLP-1 receptor agonist containing run in | Nausea | longest follow-up | Placebo | HR 4.60 (1.01 to 18.29) | 0.12 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Vomiting | longest follow-up | Placebo | HR 2.35 (0.50 to 10.22) | 0.25 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Diarrhea | longest follow-up | Placebo | HR 1.00 (0.26 to 4.20) | 0.73 |
| Weight maintenance after a GLP-1 receptor agonist containing run in | Constipation | longest follow-up | Placebo | HR 3.18 (0.75 to 12.53) | 0.24 |